Double Megatherapy and Bone Marrow Transplantation for Advanced Neuroblastoma
Author Information
Author(s): T. Philip, R. Ladenstein, J.M. Zucker, R. Pinkerton, E. Bouffet, D. Louis, W. Siegert, J.L. Bernard, D. Frappaz, C. Coze, M. Wyss, D. Beck, G. Soulliet, J. Michon, I. Philip, F. Chauvin, M. Favrot, P. Biron
Primary Institution: Centre Leon Berard
Hypothesis
Does increased dose intensity improve response status, relapse pattern, and overall survival in advanced neuroblastoma patients?
Conclusion
The double megatherapy approach achieved a 36% survival rate at 2 years and 32% at 5 years, indicating potential benefits for patients with advanced neuroblastoma.
Supporting Evidence
- Response rates for evaluable patients were 65% for megatherapy I and 60% for megatherapy II.
- Overall survival was 36% at 2 years and 32% at 5 years.
- Four early and four late toxic deaths were reported, indicating high morbidity.
Takeaway
Doctors tried a new treatment for kids with a serious cancer called neuroblastoma, and it helped some of them live longer.
Methodology
Patients received two different megatherapy regimens with autologous bone marrow transplantation after chemotherapy.
Potential Biases
Case selection bias cannot be excluded due to the non-randomized nature of the study.
Limitations
The study was non-randomized, and there was a high percentage of transferred patients, which may introduce bias.
Participant Demographics
33 patients (20 boys, 13 girls) with a median age of 53 months.
Want to read the original?
Access the complete publication on the publisher's website